Overview

Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction

Status:
Completed
Trial end date:
2020-09-05
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate whether valsartan/sacubitril leads to a superior improvement in endothelial function and endocrine status compared to valsartan alone.
Phase:
Phase 4
Details
Lead Sponsor:
University of Zurich
Collaborator:
Novartis Pharmaceuticals
Treatments:
LCZ 696
Valsartan